Bacterial folate synthesis pathway (null)

The bacterial folate synthesis pathway comprises a series of enzymatic reactions that convert GTP into tetrahydrofolic acid (THF), an essential cofactor required for nucleotide and amino acid biosynthesis. This process involves several key enzymes—such as GTP cyclohydrolase I, dihydroneopterin aldolase, hydroxymethyl-dihydropteridine pyrophosphokinase, dihydropteroate synthase (DHPS), dihydrofolate synthase (DHFS), and dihydrofolate reductase (DHFR)—each catalyzing distinct steps from precursor molecules like GTP, p‐aminobenzoic acid, and glutamate toward THF production. Unlike higher eukaryotes including humans—who must acquire dietary folates—bacteria rely on this de novo synthetic route. This difference underpins its value as an antimicrobial drug target; classic antibiotics such as sulfonamides and trimethoprim exploit these differences by selectively inhibiting DHPS or DHFR respectively, thereby blocking DNA replication and cell division. However, "bacterial folate synthesis" itself is not a single protein or receptor but rather denotes the collective action of multiple essential bacterial enzymes—a fact important when considering it as a therapeutic target or when seeking structured data about individual components versus the overall process. The term "Bacterial folate synthesis" refers to an entire metabolic pathway, not a single molecular target. The actual therapeutic targets are the individual enzymes within this pathway.

Other names

Bacterial folic acid biosynthesisFolate biosynthetic pathway in bacteriaTetrahydrofolate (THF) synthesis in bacteria

Drugs targeting this pathway act by inhibiting key enzymes required for de novo folic acid production, leading to impaired DNA/RNA/protein synthesis and ultimately bacterial cell death or stasis. For example, Sulfonamides are competitive inhibitors of para‐aminobenzoic acid at dihydropteroate synthase. Trimethoprim is a competitive inhibitor of dihydrofolate reductase.